Literature DB >> 19074672

Rescue of Ca2+ overload-induced left ventricular dysfunction by targeted ablation of phospholamban.

Tsuyoshi Tsuji1, Federica Del Monte, Yoshiro Yoshikawa, Takehisa Abe, Juichiro Shimizu, Chikako Nakajima-Takenaka, Shigeki Taniguchi, Roger J Hajjar, Miyako Takaki.   

Abstract

In failing hearts, a deficiency in sarco(endo)plasmic reticulum Ca2+ -ATPase (SERCA)2a results in abnormal Ca2+ handling and diminished contraction. In addition, a decrease in the phosphorylation of phospholamban (PLB) has been reported. Gene transfer of antisense PLB (asPLB) can improve contractile function in the failing human myocardium. Gene transfer of SERCA2a improves survival and the energy potential in failing hearts. The aim of present study was to evaluate whether enhancement of SERCA2a function prevents acute Ca2+ overload-induced left ventricular (LV) dysfunction in rat hearts. We ablated PLB using adenoviral gene transfer of asPLB by a new and less invasive gene delivery method, which involved a percutaneous technique. Experiments were performed on 13 excised cross-circulated rat hearts: 5 rats underwent sham operations, 4 rats underwent gene transfer of the reporter gene beta-galactosidase (Ad.beta-gal), and 4 rats underwent gene transfer of asPLB (Ad.asPLB). After clearance of high Ca2+ infused into the coronary, there was LV contractile dysfunction associated with the decreased myocardial O2 consumption per beat (Vo2) intercept (equal to decreased Vo2 for Ca2+ handling in excitation-contraction coupling) of the Vo2-systolic pressure-volume area (PVA; total mechanical energy per beat) linear relation in the hearts that underwent sham operation and had been infected with Ad.beta-gal. Hearts that had been infected with Ad.asPLB were rescued from LV contractile dysfunction associated with an unchanged Vo2 intercept of the Vo2-PVA linear relation. We conclude that SERCA2a function enhanced by adenoviral gene transfer of asPLB prevents Ca2+ overload-induced LV contractile dysfunction in terms of mechanical work and especially energetics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074672     DOI: 10.1152/ajpheart.00975.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  15 in total

Review 1.  Model-specific selection of molecular targets for heart failure gene therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Catherine E Tomasulo; Louella A Pritchette; Charles R Bridges
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

Review 2.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

3.  Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy.

Authors:  Naa-Adjeley D Ablorh; David D Thomas
Journal:  Biophys Rev       Date:  2015-01-21

Review 4.  Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability.

Authors:  Michael G Katz; Anthony S Fargnoli; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2013-04-01       Impact factor: 5.695

5.  Ablation of phospholamban and sarcolipin results in cardiac hypertrophy and decreased cardiac contractility.

Authors:  Mayilvahanan Shanmugam; Shumin Gao; Chull Hong; Nadezhda Fefelova; Martha C Nowycky; Lai-Hua Xie; Muthu Periasamy; Gopal J Babu
Journal:  Cardiovasc Res       Date:  2010-09-10       Impact factor: 10.787

Review 6.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

7.  Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

Authors:  Raffi Bekeredjian; Chad B Walton; Keith A MacCannell; Jennifer Ecker; Fred Kruse; Joel T Outten; David Sutcliffe; Robert D Gerard; Richard K Bruick; Ralph V Shohet
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

Review 8.  Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.

Authors:  Larissa Lipskaia; Elie R Chemaly; Lahouaria Hadri; Anne-Marie Lompre; Roger J Hajjar
Journal:  Expert Opin Biol Ther       Date:  2010-01       Impact factor: 4.388

Review 9.  Ion channels, transporters, and pumps as targets for heart failure therapy.

Authors:  Darshan Doshi; Steven O Marx
Journal:  J Cardiovasc Pharmacol       Date:  2009-10       Impact factor: 3.105

10.  Superoxide scavenging and Akt inhibition in myocardium ameliorate pressure overload-induced NF-κB activation and cardiac hypertrophy.

Authors:  Shawn D Hingtgen; Zhenbo Li; William Kutschke; Xin Tian; Ram V Sharma; Robin L Davisson
Journal:  Physiol Genomics       Date:  2010-01-26       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.